Patients with DLBCL often exhibit inactivating mutations and focal deletions in β2M, leading to the inhibition of MHC class I molecules (HLA-A,B, and C) expression on the cell surface. The gene discussed is B2M; the disease is diffuse large B-cell lymphoma.